SCH 58500

Drug Profile

SCH 58500

Alternative Names: p53 gene therapy - Schering-Plough; rAd/p53 - Schering-Plough; raDP-53 SCH 58500

Latest Information Update: 09 Jul 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; Schering-Plough
  • Developer Merck & Co; Ore Pharmaceuticals
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 09 Jul 2014 Discontinued - Phase-I for Bladder cancer in USA (unspecified route)
  • 09 Jul 2014 Discontinued - Phase-I for Fallopian tube cancer in USA (Intraperitoneal)
  • 09 Jul 2014 Discontinued - Phase-I for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top